Cell comprising an intein for the production of a cyclic peptide
Methods of producing cyclic peptides and splicing intermediates of peptides in a looped conformation are disclosed. The methods utilize the trans-splicing ability of split inteins to catalyze cyclization of peptides from a precursor peptide having a target peptide interposed between two portions of a split intein. The interaction of the two portions of the split intein creates a catalytically-active intein and also forces the target peptide into a loop configuration that stabilizes the ester isomer of the amino acid at the junction between one of the intein portions and the target peptide. A heteroatom from the other intein portion then reacts with the ester to form a cyclic ester intermediate. The active intein catalyzes the formation of an aminosuccinimide that liberates a cyclized form of the target peptide, which spontaneously rearranges to form the thermodynamically favored backbone cyclic peptide product. Also disclosed are nucleic acid molecules, polypeptides, methods for making cyclic peptides, methods of making libraries, and methods of screening peptides.
1. An isolated cell comprising a polypeptide comprising a carboxy-terminal portion of a split intein (C-intein), an amino-terminal portion of a split intein (N-intein), and a target peptide flanked on one end with the carboxy-terminal portion of a split intein (C-intein) and on its other end with the amino-terminal portion of a split intein (N-intein), wherein the polypeptide is selected from the group consisting of: (a) a polypeptide that spontaneously splices in the host system to yield a cyclized form of the target peptide, and (b) a splicing intermediate of a cyclized form of the target peptide.
2. The isolated cell of claim 1 , wherein the polypeptide is a polypeptide that spontaneously splices in the host system to yield a cyclized form of the target peptide.
3. The isolated cell of claim 1 , wherein the polypeptide is a splicing intermediate of a cyclized form of the target peptide.
4. The isolated cell of claim 1 , wherein the target peptide has a first end fused to the carboxy-terminal portion of a split intein (C-intein) and a second end fused to the amino-terminal portion of a split intein (N-intein).
5. The isolated cell of claim 1 , wherein both the carboxy-terminal portion of a split intein (C-intein) and the amino-terminal portion of a split intein (N-intein) are naturally-occurring split inteins.
6. The isolated cell of claim 5 , wherein both the carboxy-terminal portion of a split intein (C-intein) and the amino-terminal portion of a split intein (N-intein) are Ssp DnaE.
7. The isolated cell of claim 1 , wherein at least one of the carboxy-terminal portion of a split intein (C-intein) and the amino-terminal portion of a split intein (N -intein) is a non-naturally occurring split intein.
8. The isolated cell of claim 7 , wherein the non-naturally occurring split intein is selected from the group consisting of RecA, DnaB, Psp Pol-I, and Pfu inteins.
9. The isolated cell of claim 1 , wherein both the carboxy terminal portion of a split intein and the amino terminal portion of a split intein are non-naturally occurring split inteins.
10. The isolated cell of claim 3 , wherein the splicing intermediate is a active intein intermediate.
11. The isolated cell of claim 3 , wherein the splicing intermediate is a thioester intermediate.
12. The isolated cell of claim 3 , wherein the splicing intermediate is a lariat intermediate.